echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Kangxinuo, the first stock of Hong Kong stock vaccine, plans to apply for listing on science and Technology Innovation Board

    Kangxinuo, the first stock of Hong Kong stock vaccine, plans to apply for listing on science and Technology Innovation Board

    • Last Update: 2019-10-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today (September 14), kangxinuo biology Co., Ltd (hereinafter referred to as "kangxinuo") announced that it proposed to issue A-share and list on the Shanghai Stock Exchange's Kechuang board According to the plan, kangxinuo will, according to the needs of production and operation, use RMB 550 million of the raised funds in A-share issuance for the second phase construction of the production base, RMB 250 million for working capital and RMB 150 million for vaccine research and development In March this year, kangxinuo successfully landed on the Hong Kong Stock Exchange and became the first vaccine stock on the market of the Hong Kong stock exchange According to the public information, kangxinuo biology was founded in 2009 and is a company specializing in the research, development, production and commercialization of human vaccines In 2017, kangxinuo biology and Science College Military Medicine The Ebola virus vaccine Ad5 EBOV jointly developed by Chen Wei team of the Research Institute was approved by the original CFDA It is a virus vaccine that uses adenovirus vector technology to induce immune response Compared with other similar competitive products, Ad5 EBOV shows better stability and does not need ultra-low temperature storage conditions This is also the first recombinant Ebola virus vaccine approved for registration, and approved for emergency use and national reserves Up to now, ConocoPhillips has a total of 15 vaccines under development covering 12 disease areas (pneumonia, tuberculosis, meningitis, diphtheria) Among them, meningococcal combined vaccine (MCV) combined with tetravalent MCV (MCV4) and bivalent MCV (mcv2) have submitted new drug applications and are preparing to submit new drug applications respectively Up to the latest disclosure of the prospectus, China has no approved MCV4 Product: the MCV4 in research, which has completed the phase III clinical trial, shows significant safety in the 3-month-old group and can cover infants under 12 months of age Compared with other mcv2 approved in China, mcv2 has better safety and shows better immunogenicity in the 6-23-month-old group The research and development pipeline (picture source: Official Website of kangxinuo biology company) products of kangxinuo biology show excellent performance in clinical trials, which makes kangxinuo biology hopeful to seize the opportunity in the broad vaccine market Statistics show that from 2017 to 2030, the annual compound growth rate of public and private markets of meningococcal vaccine market in China is 9.5% and 9.8% respectively, with a total compound growth rate of 9.7% It is estimated that by 2030, the total sales revenue of meningococcal vaccine market in China will reach about 7 billion yuan In addition, kangxinuo biology is committed to developing the best DTCP vaccine for infants and young children Compared with the commonly used CO purified DTaP vaccine in China, the DTCP in research of kangxinuo biology for infants and young children has a fixed and well-defined DTCP antigen composition, and has better and more consistent immunogenicity At the same time, it is the same with the public The company is also developing a potential DTCP enhanced vaccine, which is the first in China, to replace the current DTCP vaccine used in China Up to now, on the one hand, there is no approved DTP enhanced vaccine for adolescents and adults in China On the other hand, China's DPT vaccine market is expected to expand rapidly in the next decade, and its sales revenue will increase from 1.9 billion yuan in 2017 to 82% in 2030 Billion yuan, with an average compound annual growth rate of 12.2% In the field of pneumonia, we are developing two vaccines against pneumococcal diseases, pcv13i vaccine and PBPV, and a global innovative TB booster vaccine The listing plan of the scientific and technological innovation board needs to be reviewed and approved by the general meeting of shareholders of kangxinuo biology Co., Ltd The resolution on the issuance of a shares shall be valid for 12 months from the date of deliberation and approval of the special general meeting and the class general meeting of shareholders The A-share offering will enable the company to expand its production capacity and strengthen research and development of early vaccines, according to Conoco After the listing of H shares in March 2019, the issuance of a shares enables the company to further enrich its capital base, optimize its corporate governance structure and develop financing platforms.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.